Diabetic medicine : a journal of the British Diabetic Association
-
Randomized Controlled Trial Multicenter Study
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
To investigate the efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with Type 2 diabetes mellitus inadequately controlled by a combination of metformin and pioglitazone. ⋯ Linagliptin as add-on therapy to metformin and pioglitazone produced significant and clinically meaningful improvements in glycaemic control, without an additional risk of hypoglycaemia or weight gain (Clinical Trials Registry No: NCT 00996658).
-
Observational Study
Fetal growth in relation to gestational weight gain in women with type 2 diabetes: an observational study.
To evaluate fetal growth in relation to gestational weight gain in women with Type 2 diabetes. ⋯ Infant birth weight was almost 0.5 kg higher in women with Type 2 diabetes and excessive gestational weight gain than in women with Type 2 diabetes and non-excessive weight gain.
-
To determine the extent of provision of preconception care among women with prepregnancy diabetes or women who develop gestational diabetes compared with women without diabetes and to examine the association between preconception care receipt and diabetes status, adjusting for maternal characteristics. ⋯ Although all women of reproductive age should receive preconception care, it is vital that women with known risk factors, such as those with prepregnancy diabetes and with risk factors for gestational diabetes, are counselled before pregnancy to optimize maternal and infant health outcomes. It is encouraging that women with prepregnancy diabetes report receiving preconception care more often than women on average, but preconception care is still not reaching all women at high risk.
-
To examine variation between general practices in the prescription of lipid-lowering treatment to people with screen-detected Type 2 diabetes, and associations with practice and participant characteristics and risk of cardiovascular events and all-cause mortality. ⋯ More frequent prescription of lipid-lowering treatment was associated with a lower incidence of CVD and all-cause mortality. Improved understanding of factors underlying practice variation in prescribing may enable more frequent use of lipid-lowering treatment. The results highlight the benefits of intensive treatment of people with screen-detected diabetes (Clinical Trials Registry No; NCT 00237549).